Neurogram™ is thrilled to announce that we have successfully raised US$3,300,000 in our latest funding round, marking a significant milestone in our journey as a pioneering AI research company focused on neurological health. Our mission is to empower the medical community in unraveling the complexities of the human brain, and with this capital infusion, we are well-equipped to accelerate our innovation and expand our impact worldwide. Headquartered in Atlanta and São Paulo, Neurogram™ has already achieved considerable success, including the development of an Anvisa-approved SaaS platform for EEG visualization and an advanced AI solution for detecting sleep disorder biomarkers. This groundbreaking work, developed in collaboration with Instituto do Sono – a global leader in sleep medicine – showcases our commitment to transforming neurological diagnostics.
Looking ahead, the funding will play a crucial role in propelling our ambitious projects currently in development, such as the AI system for Neuro-ICU biomarkers, cultivated in partnership with the Mayo Clinic, the world’s largest hospital network for seven consecutive years. This collaboration reaffirms our drive to leverage state-of-the-art technology in challenging clinical environments where timely diagnosis can be life-changing. Furthermore, being part of Google for Startups and supported by renowned health-focused investors such as Caffeinated Capital, Dorm Room Fund, Z Fellows, Hustle Fund, Starship Ventures, and Fusen, has strategically positioned Neurogram™ to lead the charge in integrating AI into clinical neuroscience. Our commitment to research, collaboration, and innovation continues to pave the way for enhanced patient care and groundbreaking insights into brain health, steering the future of neurology into uncharted, exciting territories.
